References
- Nemeth E F. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8(23)2077–2087
- Ashworth L E. Teriparatide [hPTH‐(1–34)]—a recombinant human parathyroid hormone fragment with anabolic actions for the treatment of osteoporosis. Formulary 2002; 37(3)129–133
- Campion J M, Maricic M J. Osteoporosis in men. Am Fam Phys 2003; 67(7)1521–1526
- Body J J, Gaich G A, Scheele W H, Kulkarni P M, Miller P D, Peretz A, Dore R K, Correa‐Rotter R, Papaioannou A, Cumming D C, Hodsman A B. A randomized double‐blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87(10)4528–4535
- Body J J. Management of primary osteoporosis. Acta Clin Belg 2002; 57(5)277–283
- Abramowicz M. Teriparatide (Forteo) for osteoporosis. Med Lett 2003; 45(1149)9–12
- Leone‐Bay A, Sato M, Paton D, Hunt A H, Sarubbi D, Carozza M, Chou J, McDonough J, Baughman R A. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001; 18(7)964–970
- Codrons V, Vanderbist F, Verbeeck R K, Arras M, Lison D, Preat V, Vanbever R. Systemic delivery of parathyroid hormone (1–34) using inhalation dry powders in rats. J Pharm Sci 2003; 92(5)938–950
- Patton J S, Trinchero P, Platz R M. Bioavailability of pulmonary delivered peptides and proteins‐alpha‐interferon, calcitonins and parathyroid hormones. J Control Release 1994; 28(1–3)79–85
- Wolff R K, Allen D L, Hughes B L, Smith H W, Chou J Z, Bowsher R R, Francis P C, Vahle J L. The case for route‐dependent toxicology comparisons: using large animal models to speed clinical development of inhaled proteins. Respir Drug Deliv 2000; 7: 163–170
- Suzuki Y, Nagase Y, Iga K, Kawase M, Oka M, Yanai S, Matsumoto Y, Nakagawa S, Fukuda T, Adachi H, Higo N, Ogawa Y. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH (1–34). J Pharm Sci 2002; 91(2)350–361
- Chang S L, Hofmann G A, Zhang L, Deftos L J, Banga A K. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J Control Release 2000; 66(2–3)127–133
- Kohno T, Murasugi N, Sakurai H, Watabe K, Nakamuta H, Koida M, Sugie Y, Nomura M, Yanagawa A. Development of a highly sensitive and specific two‐site enzyme immunoassay for parathyroid hormone (1–34): application to pharmacokinetic study on intranasal parathyroid hormone (1–4) in human. J Clin Lab Anal 1998; 12(5)268–275
- Fox J. Developments in parathyroid hormone and related peptides as bone‐formation agents. Curr Opin. Pharmacol 2002; 2(3)338–344
- Patton J S. Pulmonary delivery of drugs for bone disorders. Adv Drug Deliv Rev 2000; 42(3)239–248
- Hayden P J, Klausner M, Kubilus J, Jackson R, Roemer E J. Reproducibility of Epiairway®, a differentiated airway tissue model for pre‐clinical drug development studies. Abstracts of Papers. American Thoracic Society (ATS) International Conference, Seattle, WA, May, 19, 2003
- El‐Shafy M A, Roemer E, deMeireles J, Biswas M, Quay S C. Permeability and cytotoxicity of macromolecule from nasal formulation using EpiAirway® tissue model. AAPSPharmSci 2001; 3(3), Supplemental Abstract M2389
- Illium L. Nasal delivery: the use of animal models to predict performance in man. J Drug Target 1996; 3(6)427–442
- Quay S, Quay S C, deMeireles J, Wormuth D, Vangalla S, Biswas M. Effects of enhancers on macromolecules formulations on membrane penetration, cell viability and resistance using EpiAirway® tissue model. AAPSPharmSci 2001; 3(3), Supplemental Abstract M2388
- Hussain A A, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol 2000; 45(5)432–434
- Mundy G R, Guise T A. Hormonal control of calcium homeostasis. Clin Chem 1999; 48(B): 1347–1352
- Morley P, Whitfield J F, Willick G E, Ross V, MacLean S, Isaacs R J, Mendoza E, Barbier J R. Prolonged low‐dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats. Eur J Endocrinol 1999; 141: 70–74
- Dobnig H, Turner R T. The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138(11)4607–4612
- Arnaud S B, Goldsmith R S, Stickler G B, McCall J T, Arnaud C D. Serum parathyroid hormone and blood minerals: interrelationships in normal children. Pediat Res 1973; 7: 485–493
- Scotto‐Lavino E, Easow J, Simon S, Roemer E. An in vitro model for the rapid screening of potential components and formulations for nasal drug delivery. In Vitro Cell Dev Biol 2002; 38: 12